Dynamics in Post-pandemic Global Biosimilar Insulin Industry: Supply and Demand, Markets and Prices 2021-2027
Report Code: KNJ647389 No. of Pages: 164 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Biosimilar Insulin market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Biosimilar Insulin market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027. Segmented by Category Rapid Acting Insulins Short Acting Insulins Intermediate Insulins Long Lasting Insulins Segmented by End User/Segment Hospital Clinic Medical Center Segmented by Country North America United States Canada Mexico Europe Germany France UK Italy Russia Spain Asia Pacific China Japan Korea Southeast Asia India Australasia Central & South America Brazil Argentina Colombia Middle East & Africa Iran Israel Turkey South Africa Saudi Arabia Key manufacturers included in this survey Wockhardt Teva Pharmaceuticals Sedico Samsung Bioepis Pfizer Paras Biopharmaceuticals Julphar Gulf Pharmaceutical Industries Geropharm Gan&Lee Pharmaceuticals Eli Lilly Biogenomics
Table of Contents
1 Product Introduction and Overview
1.1 Product Definition
1.2 Product Specification
1.3 Global Market Overview
1.3.1 Global Biosimilar Insulin Market Status and Forecast (2016-2027)
1.3.2 Global Biosimilar Insulin Sales Value CAGR by Region
1.4 Market Drivers, Inhibitors
1.4.1 Market Drivers
1.4.2 Market Inhibitors
1.4.3 COVID-19 Impact Analysis
2 Global Biosimilar Insulin Supply by Company
2.1 Global Biosimilar Insulin Sales Volume by Company
2.2 Global Biosimilar Insulin Sales Value by Company
2.3 Global Biosimilar Insulin Price by Company
2.4 Biosimilar Insulin Production Location and Sales Area of Main Manufacturers
2.5 Trend of Concentration Rate
3 Global and Regional Biosimilar Insulin Market Status by Category
3.1 Biosimilar Insulin Category Introduction
3.1.1 Rapid Acting Insulins
3.1.2 Short Acting Insulins
3.1.3 Intermediate Insulins
3.1.4 Long Lasting Insulins
3.2 Global Biosimilar Insulin Market by Category
3.2.1 Global Biosimilar Insulin Sales Volume by Category (2016-2021)
3.2.2 Global Biosimilar Insulin Sales Value by Category (2016-2021)
3.2.3 Global Biosimilar Insulin Price by Category (2016-2021)
3.3 North America: by Category
3.4 Europe: by Category
3.5 Asia Pacific: by Category
3.6 Central & South America: by Category
3.7 Middle East & Africa: by Category
4 Global and Regional Biosimilar Insulin Market Status by End User/Segment
4.1 Biosimilar Insulin Segment by End User/Segment
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Medical Center
4.2 Global Biosimilar Insulin Market by End User/Segment
4.2.1 Global Biosimilar Insulin Sales Volume by End User/Segment (2016-2021)
4.2.2 Global Biosimilar Insulin Sales Value by End User/Segment (2016-2021)
4.2.3 Global Biosimilar Insulin Price by End User/Segment (2016-2021)
4.3 North America: by End User/Segment
4.4 Europe: by End User/Segment
4.5 Asia Pacific: by End User/Segment
4.6 Central & South America: by End User/Segment
4.7 Middle East & Africa: by End User/Segment
5 Global Biosimilar Insulin Market Status by Region
5.1 Global Biosimilar Insulin Market by Region
5.1.1 Global Biosimilar Insulin Sales Volume by Region
5.1.2 Global Biosimilar Insulin Sales Value by Region
5.2 North America Biosimilar Insulin Market Status
5.3 Europe Biosimilar Insulin Market Status
5.4 Asia Pacific Biosimilar Insulin Market Status
5.5 Central & South America Biosimilar Insulin Market Status
5.6 Middle East & Africa Biosimilar Insulin Market Status
6 North America Biosimilar Insulin Market Status
6.1 North America Biosimilar Insulin Market by Country
6.1.1 North America Biosimilar Insulin Sales Volume by Country (2016-2021)
6.1.2 North America Biosimilar Insulin Sales Value by Country (2016-2021)
6.2 United States
6.3 Canada
6.4 Mexico
7 Europe Biosimilar Insulin Market Status
7.1 Europe Biosimilar Insulin Market by Country
7.1.1 Europe Biosimilar Insulin Sales Volume by Country (2016-2021)
7.1.2 Europe Biosimilar Insulin Sales Value by Country (2016-2021)
7.2 Germany
7.3 France
7.4 UK
7.5 Italy
7.6 Russia
7.7 Spain
8 Asia Pacific Biosimilar Insulin Market Status
8.1 Asia Pacific Biosimilar Insulin Market by Country
8.1.1 Asia Pacific Biosimilar Insulin Sales Volume by Country (2016-2021)
8.1.2 Asia Pacific Biosimilar Insulin Sales Value by Country (2016-2021)
8.2 China
8.3 Japan
8.4 Korea
8.5 Southeast Asia
8.6 India
8.7 Australasia
9 Central & South America Biosimilar Insulin Market Status
9.1 Central & South America Biosimilar Insulin Market by Country
9.1.1 Central & South America Biosimilar Insulin Sales Volume by Country (2016-2021)
9.1.2 Central & South America Biosimilar Insulin Sales Value by Country (2016-2021)
9.2 Brazil
9.3 Argentina
9.4 Colombia
10 Middle East & Africa Biosimilar Insulin Market Status
10.1 Middle East & Africa Biosimilar Insulin Market by Country
10.1.1 Middle East & Africa Biosimilar Insulin Sales Volume by Country (2016-2021)
10.1.2 Middle East & Africa Biosimilar Insulin Sales Value by Country (2016-2021)
10.2 Iran
10.3 Israel
10.4 Turkey
10.5 South Africa
10.8 Saudi Arabia
11 Supply Chain and Manufacturing Cost Analysis
11.1 Supply Chain Analysis
11.2 Production Process Chart Analysis
11.3 Raw Materials and Key Suppliers Analysis
11.3.1 Raw Materials Introduction
11.3.2 Raw Materials Key Suppliers List
11.4 Biosimilar Insulin Manufacturing Cost Analysis
11.5 Biosimilar Insulin Sales Channel and Distributors Analysis
11.5.1 Biosimilar Insulin Sales Channel
11.5.2 Biosimilar Insulin Distributors
11.6 Biosimilar Insulin Downstream Major Buyers
12 Global Biosimilar Insulin Market Forecast by Category and by End User/Segment
12.1 Global Biosimilar Insulin Sales Volume and Sales Value Forecast (2022-2027)
12.2 Global Biosimilar Insulin Forecast by Category
12.2.1 Global Biosimilar Insulin Sales Volume Forecast by Category
12.2.2 Global Biosimilar Insulin Sales Value Forecast by Category
12.2.3 Global Biosimilar Insulin Price Forecast by Category
12.3 Global Biosimilar Insulin Forecast by End User/Segment
12.3.1 Global Biosimilar Insulin Sales Volume Forecast by End User/Segment
12.3.2 Global Biosimilar Insulin Sales Value Forecast by End User/Segment
12.3.3 Global Biosimilar Insulin Price Forecast by End User/Segment
13 Global Biosimilar Insulin Market Forecast by Region/Country
13.1 Global Biosimilar Insulin Market Forecast by Region (2022-2027)
13.1.1 Global Biosimilar Insulin Sales Volume Forecast by Region (2022-2027)
13.1.2 Global Biosimilar Insulin Sales Value Forecast by Region (2022-2027)
13.2 North America Market Forecast
13.3 Europe Market Forecast
13.4 Asia Pacific Market Forecast
13.5 Central & South America Market Forecast
13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
14.1 Wockhardt
14.1.1 Company Information
14.1.2 Biosimilar Insulin Product Introduction
14.1.3 Wockhardt
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.1.4 SWOT Analysis
14.2 Teva Pharmaceuticals
14.2.1 Company Information
14.2.2 Biosimilar Insulin Product Introduction
14.2.3 Teva Pharmaceuticals Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.2.4 SWOT Analysis
14.3 Sedico
14.3.1 Company Information
14.3.2 Biosimilar Insulin Product Introduction
14.3.3 Sedico
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.3.4 SWOT Analysis
14.4 Samsung Bioepis
14.4.1 Company Information
14.4.2 Biosimilar Insulin Product Introduction
14.4.3 Samsung Bioepis
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.4.4 SWOT Analysis
14.5 Pfizer
14.5.1 Company Information
14.5.2 Biosimilar Insulin Product Introduction
14.5.3 Pfizer
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.5.4 SWOT Analysis
14.6 Paras Biopharmaceuticals
14.6.1 Company Information
14.6.2 Biosimilar Insulin Product Introduction
14.6.3 Paras Biopharmaceuticals
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.6.4 SWOT Analysis
14.7 Julphar Gulf Pharmaceutical Industries
14.7.1 Company Information
14.7.2 Biosimilar Insulin Product Introduction
14.7.3 Julphar Gulf Pharmaceutical Industries
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.7.4 SWOT Analysis
14.8 Geropharm
14.8.1 Company Information
14.8.2 Biosimilar Insulin Product Introduction
14.8.3 Geropharm
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.8.4 SWOT Analysis
14.9 Gan&Lee Pharmaceuticals
14.9.1 Company Information
14.9.2 Biosimilar Insulin Product Introduction
14.9.3 Gan&Lee Pharmaceuticals
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.9.4 SWOT Analysis
14.10 Eli Lilly
14.10.1 Company Information
14.10.2 Biosimilar Insulin Product Introduction
14.10.3 Eli Lilly
Biosimilar Insulin Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.10.4 SWOT Analysis
14.11 Biogenomics
15 Conclusion
16 Methodology
List of Tables and Figures
Ask Sample Report to get more details… NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com